Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Enterprise Value (2022 - 2025)

Historic Enterprise Value for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to -$451.6 million.

  • Day One Biopharmaceuticals' Enterprise Value rose 1912.72% to -$451.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$451.6 million, marking a year-over-year increase of 1912.72%. This contributed to the annual value of -$531.7 million for FY2024, which is 4514.11% down from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Enterprise Value of -$451.6 million as of Q3 2025, which was up 1912.72% from -$453.1 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Enterprise Value high stood at -$262.7 million for Q1 2022, and its period low was -$558.4 million during Q3 2024.
  • For the 4-year period, Day One Biopharmaceuticals' Enterprise Value averaged around -$403.3 million, with its median value being -$388.9 million (2022).
  • Over the last 5 years, Day One Biopharmaceuticals' Enterprise Value had its largest YoY gain of 1912.72% in 2025, and its largest YoY loss of 4877.46% in 2025.
  • Day One Biopharmaceuticals' Enterprise Value (Quarter) stood at -$342.3 million in 2022, then fell by 7.03% to -$366.3 million in 2023, then tumbled by 45.14% to -$531.7 million in 2024, then grew by 15.07% to -$451.6 million in 2025.
  • Its Enterprise Value stands at -$451.6 million for Q3 2025, versus -$453.1 million for Q2 2025 and -$473.0 million for Q1 2025.